[HTML][HTML] A narrative literature review of bias in collecting patient reported outcomes measures (PROMs)

MLL Zini, G Banfi - International journal of environmental research and …, 2021 - mdpi.com
There is a growing interest in the collection and use of patient reported outcomes because
they not only provide clinicians with crucial information, but can also be used for economic …

Levodopa in Parkinson's disease: from the past to the future

G Pezzoli, M Zini - Expert opinion on pharmacotherapy, 2010 - Taylor & Francis
Importance of the field: Levodopa is the mainstay of symptomatic treatment for Parkinson's
disease (PD). Although other treatments have been developed in the last 30 years, most …

Survival and dementia in GBA‐associated Parkinson's disease: The mutation matters

R Cilia, S Tunesi, G Marotta, E Cereda… - Annals of …, 2016 - Wiley Online Library
Objective The objective of this work was to investigate survival, dementia, and genotype‐
phenotype correlations in patients with Parkinson's disease (PD) with and without mutations …

Swallowing disturbances in Parkinson's disease: a multivariate analysis of contributing factors

E Cereda, R Cilia, C Klersy, M Canesi… - Parkinsonism & Related …, 2014 - Elsevier
Background Swallowing disturbances are an important issue in Parkinson's disease (PD) as
several studies have shown that they are associated with increased risk of aspiration …

[HTML][HTML] The Gly2019Ser mutation in LRRK2is not fully penetrant in familial Parkinson's disease: the GenePD study

JC Latourelle, M Sun, MF Lew, O Suchowersky, C Klein… - BMC medicine, 2008 - Springer
Background We report age-dependent penetrance estimates for leucine-rich repeat kinase 2
(LRRK2)-related Parkinson's disease (PD) in a large sample of familial PD. The most …

Dementia in Parkinson's disease: Is male gender a risk factor?

E Cereda, R Cilia, C Klersy, C Siri, B Pozzi… - Parkinsonism & related …, 2016 - Elsevier
Background The rates of cognitive decline in patients with Parkinson's disease (PD) are
higher than in the general population. Age and disease duration have been associated with …

LRRK2 G2019S mutation and Parkinson's disease: a clinical, neuropsychological and neuropsychiatric study in a large Italian sample

S Goldwurm, M Zini, A Di Fonzo, D De Gaspari… - Parkinsonism & related …, 2006 - Elsevier
We analysed the Leucine-Rich Repeat Kinase 2 (LRRK2) gene for the G2019S mutation in
1245 consecutive, unrelated patients with primary degenerative parkinsonism, and collected …

Dopamine dysregulation syndrome in Parkinson's disease: from clinical and neuropsychological characterisation to management and long-term outcome

R Cilia, C Siri, M Canesi, AL Zecchinelli… - Journal of Neurology …, 2014 - jnnp.bmj.com
Objective Dopamine dysregulation syndrome (DDS) refers to a compulsive pattern of
dopaminergic drug misuse complicating Parkinson's disease (PD). To date, few data are …

Parkinson's disease beyond 20 years

R Cilia, E Cereda, C Klersy, M Canesi… - Journal of Neurology …, 2015 - jnnp.bmj.com
Background A very limited number of studies report data on the clinical features of
Parkinson's disease (PD) 20 years after onset and beyond. Objective To characterise PD 20 …

[HTML][HTML] LRRK2 mutations in Parkinson's disease: confirmation of a gender effect in the Italian population

R Cilia, C Siri, D Rusconi, R Allegra, A Ghiglietti… - Parkinsonism & related …, 2014 - Elsevier
Background The relative risk of developing idiopathic PD is 1.5 times greater in men than in
women, but an increased female prevalence in LRRK2-carriers has been described in the …